Compare Piramal Healthcare with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs SUN PHARMA - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES SUN PHARMA PIRAMAL ENTERPRISES/
SUN PHARMA
 
P/E (TTM) x 13.5 26.0 52.1% View Chart
P/BV x 0.9 2.2 38.3% View Chart
Dividend Yield % 2.1 0.7 289.4%  

Financials

 PIRAMAL ENTERPRISES   SUN PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
SUN PHARMA
Mar-19
PIRAMAL ENTERPRISES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs3,303679 486.5%   
Low Rs1,797375 478.6%   
Sales per share (Unadj.) Rs716.5121.1 591.4%  
Earnings per share (Unadj.) Rs79.713.4 595.9%  
Cash flow per share (Unadj.) Rs107.920.7 521.7%  
Dividends per share (Unadj.) Rs28.002.75 1,018.2%  
Dividend yield (eoy) %1.10.5 210.5%  
Book value per share (Unadj.) Rs1,477.5172.6 856.1%  
Shares outstanding (eoy) m184.452,399.26 7.7%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x3.64.4 81.8%   
Avg P/E ratio x32.039.4 81.2%  
P/CF ratio (eoy) x23.625.5 92.7%  
Price / Book Value ratio x1.73.1 56.5%  
Dividend payout %35.120.6 170.9%   
Avg Mkt Cap Rs m470,2921,264,650 37.2%   
No. of employees `0007.817.5 44.7%   
Total wages/salary Rs m22,50459,671 37.7%   
Avg. sales/employee Rs Th16,899.416,608.1 101.8%   
Avg. wages/employee Rs Th2,877.73,409.6 84.4%   
Avg. net profit/employee Rs Th1,879.91,833.8 102.5%   
INCOME DATA
Net Sales Rs m132,153290,659 45.5%  
Other income Rs m3,12810,255 30.5%   
Total revenues Rs m135,281300,914 45.0%   
Gross profit Rs m66,29063,076 105.1%  
Depreciation Rs m5,20217,533 29.7%   
Interest Rs m44,0975,553 794.2%   
Profit before tax Rs m20,11950,246 40.0%   
Minority Interest Rs m3,1940-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m8,6116,009 143.3%   
Profit after tax Rs m14,70132,093 45.8%  
Gross profit margin %50.221.7 231.1%  
Effective tax rate %42.812.0 357.9%   
Net profit margin %11.111.0 100.8%  
BALANCE SHEET DATA
Current assets Rs m122,742310,692 39.5%   
Current liabilities Rs m310,810173,396 179.2%   
Net working cap to sales %-142.347.2 -301.3%  
Current ratio x0.41.8 22.0%  
Inventory Days Days2399 23.3%  
Debtors Days Days39112 34.8%  
Net fixed assets Rs m116,904232,477 50.3%   
Share capital Rs m3692,399 15.4%   
"Free" reserves Rs m272,161411,691 66.1%   
Net worth Rs m272,530414,091 65.8%   
Long term debt Rs m270,19615,226 1,774.6%   
Total assets Rs m856,261646,938 132.4%  
Interest coverage x1.510.0 14.5%   
Debt to equity ratio x1.00 2,696.3%  
Sales to assets ratio x0.20.4 34.4%   
Return on assets %6.95.8 118.0%  
Return on equity %5.47.8 69.6%  
Return on capital %12.410.2 122.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,20066,025 23.0%   
Fx outflow Rs m4,88938,610 12.7%   
Net fx Rs m10,31227,415 37.6%   
CASH FLOW
From Operations Rs m-115,97521,965 -528.0%  
From Investments Rs m-8,265-6,813 121.3%  
From Financial Activity Rs m107,525-27,305 -393.8%  
Net Cashflow Rs m-16,650-8,442 197.2%  

Share Holding

Indian Promoters % 52.9 63.7 83.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 5.1 78.0%  
FIIs % 26.6 23.0 115.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 8.3 198.8%  
Shareholders   93,274 133,026 70.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   SHASUN PHARMA  WYETH LTD  TORRENT PHARMA  UNICHEM LAB  DR. REDDYS LAB  

Compare PIRAMAL ENTERPRISES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

What Should You Do in Today's Volatile Markets?(Podcast)

The week gone by was pretty volatile for Dalal street and the global environment is as unpredictable as it can get.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Small Cap Stocks Could Triple in Less than 2 Years... Here's Why(Profit Hunter)

Sep 30, 2019

Historical data backs up my conviction.

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Interest Rates Are Low. Buy Solid Dividend Stocks Instead(The 5 Minute Wrapup)

Sep 30, 2019

Select dividend stocks can be very rewarding.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Oct 11, 2019 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES - PANACEA BIOTECH COMPARISON

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS